Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398372 · ClinicalTrials.gov registry record · NA
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
A NA study of Lymphoma, Non-Hodgkin and Lymphomas: Non-Hodgkin, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT00398372 is a NA study of Lymphoma, Non-Hodgkin and Lymphomas: Non-Hodgkin that has completed, run by Stanford University. The registered enrollment target is 500 participants, above the 385-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00398372, a NA study of Lymphoma, Non-Hodgkin and Lymphomas: Non-Hodgkin, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Epratuzumab
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2000-11 |
| Est. Completion | 2009-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00398372
The ClinicalTrials.gov registry entry for NCT00398372 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 385-participant average among 56 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (30% higher). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT00398372 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00398372 about?
NCT00398372 is a clinical study titled "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment". To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
What is the current status of trial NCT00398372?
This trial is currently completed. It is a NA study. The enrollment target is 500 participants. The study started on 2000-11. Estimated completion is 2009-09.
What conditions does trial NCT00398372 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Lymphomas: Non-Hodgkin, Lymphomas: Non-Hodgkin Cutaneous Lymphoma, Lymphomas: Non-Hodgkin Diffuse Large B-Cell, Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell.
What interventions are being tested in trial NCT00398372?
The interventions under investigation include: Rituximab (DRUG), Epratuzumab (DRUG).
Who is sponsoring clinical trial NCT00398372?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00398372 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
RECRUITING · NA
-
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
ACTIVE NOT RECRUITING · NA
-
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
COMPLETED · NA
-
A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant
COMPLETED · NA
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.